- Home
- HWH vs NXTC Comparison
HWH vs NXTC Comparison
Compare HWH & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWH
- NXTC
- Stock Information
- Founded
- HWH 2021
- NXTC 2015
- Country
- HWH United States
- NXTC United States
- Employees
- HWH N/A
- NXTC N/A
- Industry
- HWH Other Pharmaceuticals
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- HWH Health Care
- NXTC Health Care
- Exchange
- HWH Nasdaq
- NXTC Nasdaq
- Market Cap
- HWH 21.2M
- NXTC 20.6M
- IPO Year
- HWH N/A
- NXTC 2019
- Fundamental
- Price
- HWH $1.23
- NXTC $0.40
- Analyst Decision
- HWH
- NXTC Strong Buy
- Analyst Count
- HWH 0
- NXTC 2
- Target Price
- HWH N/A
- NXTC $3.50
- AVG Volume (30 Days)
- HWH 582.3K
- NXTC 99.1K
- Earning Date
- HWH 05-14-2025
- NXTC 03-06-2025
- Dividend Yield
- HWH N/A
- NXTC N/A
- EPS Growth
- HWH N/A
- NXTC N/A
- EPS
- HWH N/A
- NXTC N/A
- Revenue
- HWH $1,253,577.00
- NXTC N/A
- Revenue This Year
- HWH N/A
- NXTC N/A
- Revenue Next Year
- HWH N/A
- NXTC N/A
- P/E Ratio
- HWH N/A
- NXTC N/A
- Revenue Growth
- HWH 50.94
- NXTC N/A
- 52 Week Low
- HWH $1.17
- NXTC $0.35
- 52 Week High
- HWH $15.75
- NXTC $2.49
- Technical
- Relative Strength Index (RSI)
- HWH 38.32
- NXTC 22.20
- Support Level
- HWH $1.18
- NXTC $0.49
- Resistance Level
- HWH $1.36
- NXTC $0.67
- Average True Range (ATR)
- HWH 0.17
- NXTC 0.09
- MACD
- HWH -0.02
- NXTC -0.02
- Stochastic Oscillator
- HWH 10.37
- NXTC 12.74
About HWH HWH International Inc.
HWH International Inc is a purpose-driven lifestyle company enabling home-based people in the new GIG economy to create lasting wealth. Developing new pathways in the aid of helping people in their pursuit of Health, Wealth and Happiness.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.